Companies
-
Oz Novavax shots likely to be European
- 12 Apr 2021
With 51 million doses on order, Australia will have to depend on OS supplies – and they won’t arrive until later this year.
Read more -
Together again: Celgene A-team reunites
- 07 Apr 2021
Six execs are back together with the newest kid on the blood cancer block, start-up biopharma Antengene, backing its first market entry with their decades of experience.
Read more -
Alzheimer drug expected 2022
- 07 Apr 2021
Two companion tests for Biogen’s first-in-class drug have begun their funding journey with aducanumab on track for 2022.
Read more -
Rare cancer drugs star at slim PBAC meet
- 01 Apr 2021
Twelve new drugs mark smallest agenda in three years, with a heavy focus on rare diseases.
Read more -
Pfizer moves in biosimilars
- 01 Apr 2021
Following a star global performance in the Covid vaccine race, Pfizer’s July PBAC showing is much less inspiring.
Read more -
A 10 year journey to ‘dream job’
- 31 Mar 2021
New Sanofi recruit Dr Amit Lalwani describes how becoming an MSL was a decade in the making, and what it’s like now he’s there.
Read more -
Novartis fined $200k for eye promotion
- 31 Mar 2021
Novartis’ attempt to move in on Bayer’s Eylea resulted in it being the last company fined under the outgoing MA Code.
Read more -
Costs awarded in Lexapro case
- 31 Mar 2021
Long-running court battle resulting from a generic launched over a decade ago continues to play out.
Read more